Organon & Co.

NYSE:OGN Stock Report

Market Cap: US$2.5b

Organon Future Growth

Future criteria checks 2/6

Organon is forecast to grow earnings and revenue by 14.5% and 1.1% per annum respectively. EPS is expected to grow by 13.9% per annum. Return on equity is forecast to be 38.6% in 3 years.

Key information

14.5%

Earnings growth rate

13.92%

EPS growth rate

Pharmaceuticals earnings growth12.4%
Revenue growth rate1.1%
Future return on equity38.56%
Analyst coverage

Good

Last updated28 Aug 2025

Recent future growth updates

Recent updates

Organon: Valuation Discount Offset By Structural Headwinds

Aug 12

Why Investors Shouldn't Be Surprised By Organon & Co.'s (NYSE:OGN) 30% Share Price Plunge

May 08
Why Investors Shouldn't Be Surprised By Organon & Co.'s (NYSE:OGN) 30% Share Price Plunge

Organon's (NYSE:OGN) Dividend Is Being Reduced To $0.02

May 04
Organon's (NYSE:OGN) Dividend Is Being Reduced To $0.02

Organon (NYSE:OGN) Use Of Debt Could Be Considered Risky

Apr 28
Organon (NYSE:OGN) Use Of Debt Could Be Considered Risky

Earnings Working Against Organon & Co.'s (NYSE:OGN) Share Price

Mar 24
Earnings Working Against Organon & Co.'s (NYSE:OGN) Share Price

Why Organon Is A Top Pick For Income Investors

Mar 18

Organon's (NYSE:OGN) Dividend Will Be $0.28

Feb 17
Organon's (NYSE:OGN) Dividend Will Be $0.28

Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield

Jan 17

Earnings Working Against Organon & Co.'s (NYSE:OGN) Share Price

Dec 13
Earnings Working Against Organon & Co.'s (NYSE:OGN) Share Price

Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)

Nov 13

The Organon & Co. (NYSE:OGN) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Nov 04
The Organon & Co. (NYSE:OGN) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis

Sep 19

These 4 Measures Indicate That Organon (NYSE:OGN) Is Using Debt In A Risky Way

Sep 13
These 4 Measures Indicate That Organon (NYSE:OGN) Is Using Debt In A Risky Way
User avatar

NEXPLANON And Biosimilars Drive Growth Amid Financial And Market Challenges

NEXPLANON's efficacy and expansion into new international markets are expected to drive significant revenue growth in women's health.

Organon & Co.: Cheap With Caveats

Aug 22

Organon (NYSE:OGN) Will Pay A Dividend Of $0.28

Aug 09
Organon (NYSE:OGN) Will Pay A Dividend Of $0.28

Insufficient Growth At Organon & Co. (NYSE:OGN) Hampers Share Price

Aug 07
Insufficient Growth At Organon & Co. (NYSE:OGN) Hampers Share Price

Organon: Upcoming Q2 Earnings Can Sustain Upward Momentum

Jul 30

Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year

May 29
Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year

Organon's (NYSE:OGN) Solid Profits Have Weak Fundamentals

May 10
Organon's (NYSE:OGN) Solid Profits Have Weak Fundamentals

Four Reasons Why Organon Stock Is A Good Buy

May 07

Little Excitement Around Organon & Co.'s (NYSE:OGN) Earnings

Apr 21
Little Excitement Around Organon & Co.'s (NYSE:OGN) Earnings

Organon Stock Is Still Worth A Look

Feb 24

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Feb 19
Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last

Feb 16

Organon: What I'm Looking For In This 8% Yield In 2024

Jan 03

High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued

Dec 19

Organon: It's Darkest Before The Dawn

Nov 30

Earnings and Revenue Growth Forecasts

NYSE:OGN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20276,4069521,1241,1725
12/31/20266,3208489619566
12/31/20256,2695727718976
6/30/20256,281700482826N/A
3/31/20256,294750586938N/A
12/31/20246,403864588939N/A
9/30/20246,4091,301646946N/A
6/30/20246,3461,0007871,066N/A
3/31/20246,3471,047458761N/A
12/31/20236,2631,023538799N/A
9/30/20236,150585424669N/A
6/30/20236,168754320725N/A
3/31/20236,145746431849N/A
12/31/20226,174917431858N/A
9/30/20226,2921,011138638N/A
6/30/20226,3551,107343689N/A
3/31/20226,3651,3045641,077N/A
12/31/20216,3041,3511,9702,458N/A
9/30/20216,3141,5252,3702,841N/A
6/30/20216,3271,7622,3042,761N/A
3/31/20216,2581,9172,7723,025N/A
12/31/20206,5322,2561,9322,187N/A
12/31/20197,7773,3062,6752,767N/A
12/31/20189,7772,153N/A3,687N/A
12/31/201710,5001,801N/A3,419N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OGN's forecast earnings growth (14.5% per year) is above the savings rate (3.1%).

Earnings vs Market: OGN's earnings (14.5% per year) are forecast to grow slower than the US market (15.1% per year).

High Growth Earnings: OGN's earnings are forecast to grow, but not significantly.

Revenue vs Market: OGN's revenue (1.1% per year) is forecast to grow slower than the US market (9.3% per year).

High Growth Revenue: OGN's revenue (1.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: OGN's Return on Equity is forecast to be high in 3 years time (38.6%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/05 21:38
End of Day Share Price 2025/09/05 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Organon & Co. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Navann Ty DietschiBNP Paribas Exane
Jason Matthew GerberryBofA Global Research
Sel HardyCFRA Equity Research